A Phase 2 Study of XL999 Administered Intravenously to Subjects With Metastatic Renal Cell Carcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Inclusion until disease progression
No
Lynne A. Bui, MD
Study Director
Exelixis, Inc.
United States: Food and Drug Administration
XL999-201
NCT00277316
December 2005
June 2007
Name | Location |
---|---|
Stanford Cancer Center | Stanford, California 94305-5824 |
Integrated Community Oncology Network | Jacksonville Beach, Florida 32250 |
University of Chicago | Chicago, Illinois 60637 |
The Center for Cancer and Blood Disorders | Fort Worth, Texas 76104 |
Center for Oncology Research and Treatment, PA | Dallas, Texas 75230 |
The Cleveland Clinic Foundation Taussig Cancer Center | Cleveland, Ohio 44195 |
Joliet Oncology-Hematology Associates, Ltd | Joliet, Illinois 60435 |
Department of Hematology/Oncology | Los Angeles, California 90095 |
Division of Hematology/Oncology, Indiana University Cancer Center | Indianapolis, Indiana 46202 |